SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-21-005129
Filing Date
2021-03-01
Accepted
2021-03-01 17:20:37
Documents
71
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm 10-K 2065209
2 ex4-1.htm EX-4.1 85967
3 ex21-1.htm EX-21.1 7536
4 ex23-1.htm EX-23.1 3428
5 ex31-1.htm EX-31.1 18383
6 ex31-2.htm EX-31.2 17931
7 ex32-1.htm EX-32.1 6294
8 ex32-2.htm EX-32.2 6161
  Complete submission text file 0001493152-21-005129.txt   8138108

Data Files

Seq Description Document Type Size
9 XBRL INSTANCE FILE aker-20201231.xml EX-101.INS 1187086
10 XBRL SCHEMA FILE aker-20201231.xsd EX-101.SCH 110102
11 XBRL CALCULATION FILE aker-20201231_cal.xml EX-101.CAL 65937
12 XBRL DEFINITION FILE aker-20201231_def.xml EX-101.DEF 374123
13 XBRL LABEL FILE aker-20201231_lab.xml EX-101.LAB 676093
14 XBRL PRESENTATION FILE aker-20201231_pre.xml EX-101.PRE 443775
Mailing Address 1185 AVENUE OF THE AMERICAS 3RD FLOOR NEW YORK NY 10036
Business Address 1185 AVENUE OF THE AMERICAS 3RD FLOOR NEW YORK NY 10036 856-848-8698
Akers Biosciences, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-36268 | Film No.: 21699444
SIC: 2835 In Vitro & In Vivo Diagnostic Substances